The US Food and Drug Administration (FDA) is taking a new step in contributing to psychedelic research, publishing its first draft of guidance measures outlining recommendations to the pharmaceutical industry for designing clinical trials on psychedelic drugs.
This new set of recommendations covers studies including what the FDA defines as “classic” psychedelics like Psylocibin (the psychoactive component found in magic mushrooms) and LSD (aka “Acid”) as well as the empathogen MDMA.
While commonly associated with recreational use in settings like clubs and music festivals, the…
